Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Improving Equitable Access to Penicillin Allergy De-Labeling

Award Number: R01HS029319
ORGANIZATION: AGENCY FOR HEALTH CARE RESEARCH AND QUALITY
OPDIV: AHRQ
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2023
PERIOD OF PERFORMANCE END DATE: 02/29/2028

Group Awards By:

View Award Description

Improving Equitable Access to Penicillin Allergy De-Labeling - Project Summary The global public health strategy to decrease mortality from antimicrobial resistant (AMR) infections encourages removal of inaccurate penicillin (PCN) allergy labels, termed “de-labeling.” PCN allergy de-labeling is recommended as ~10% of all people report a PCN allergy, but only 5% of those (i.e., <1%) have a true PCN allergy confirmed after formal testing. Prescription of alternative antibiotics in individuals with PCN allergy labels results in inferior clinical outcomes, increased adverse events including Clostridioides difficile infection, increased methicillin-resistant Staphylococcus aureus, and increased health care costs. PCN allergy de- labeling is an evidence-based strategy that can decrease exposure to more broad-spectrum and suboptimal antibiotics, potentially reducing multi-drug resistant and healthcare-associated infections and saving lives. Most efforts to improve access to PCN allergy de-labeling have been reactive in acute care settings at the time of antibiotic need, rather than proactive in ambulatory care settings. Furthermore, PCN allergy de-labeling efforts to date have not focused on health care equity despite AMR rates being highest in minoritized communities. This application focuses on identifying feasible and acceptable strategies to increase equitable access to PCN allergy de-labeling. Our long-term goal is to decrease AMR infections with a purposeful focus on reducing infection-associated health disparities. This study considers three Boston-based hospital networks serving diverse communities and with disparate allergy specialist access for studies that aim to improve equitable access to PCN allergy de-labeling. Our specific research aims include: 1) determining patient, societal, clinician, and institutional factors associated with PCN allergy de-labeling; 2) investigating barriers and facilitators to PCN allergy de-labeling in primary care with qualitative methods; and 3) identification, refining, and evaluating implementation strategies to increase equitable access to PCN allergy de-labeling. To achieve these aims, we leverage a multidisciplinary research team comprised of leaders in infectious diseases, allergy/immunology, primary care, and health disparities with broad methodologic expertise in large database research, qualitative research, and implementation science. This application is responsive to PA-22-047, aligns with the mission of AHRQ, and our universal commitments to improve health care, make health care more equitable, and reduce the global crisis of antimicrobial resistance.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $249,967 )
2025	2025	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Research on Healthcare Costs, Quality and Outcomes	002	4	2/21/2025	NON-COMPETING CONTINUATION	$249,967
2025	2024	TUFTS MEDICAL CENTER PARENT, INC.	800 WASHINGTON ST	BOSTON	MA	02111	SUFFOLK	USA	Research on Healthcare Costs, Quality and Outcomes	000	2	11/12/2024	NON-COMPETING CONTINUATION	-$3,853
2025	2024	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Research on Healthcare Costs, Quality and Outcomes	001	3	11/12/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$3,853
														Subtotal = $249,967

Issue Date FY: 2024 ( Subtotal = $499,933 )
2024	2024	TUFTS MEDICAL CENTER PARENT, INC.	800 WASHINGTON ST	BOSTON	MA	02111	SUFFOLK	USA	Research on Healthcare Costs, Quality and Outcomes	001	2	8/1/2024	NON-COMPETING CONTINUATION	$0
2024	2024	TUFTS MEDICAL CENTER PARENT, INC.	800 WASHINGTON ST	BOSTON	MA	02111	SUFFOLK	USA	Research on Healthcare Costs, Quality and Outcomes	000	2	2/14/2024	NON-COMPETING CONTINUATION	$499,933
														Subtotal = $499,933

Issue Date FY: 2023 ( Subtotal = $497,778 )
2023	2023	TUFTS MEDICAL CENTER, INC.	800 WASHINGTON ST	BOSTON	MA	02111	SUFFOLK	USA	Research on Healthcare Costs, Quality and Outcomes	000	1	4/18/2023	NEW	$497,778
														Subtotal = $497,778

Grand Total All Awards = $1,247,678

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Improving Equitable Access to Penicillin Allergy De-Labeling

Award Number: R01HS029319

ORGANIZATION: AGENCY FOR HEALTH CARE RESEARCH AND QUALITY

OPDIV: AHRQ

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2023

PERIOD OF PERFORMANCE END DATE: 02/29/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer